Elutia Inc
NASDAQ:ELUT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Q
|
Qualcomm Inc
LSE:0QZ3
|
US |
|
Ibersol SGPS SA
LSE:0KJ7
|
PT |
|
Guangdong Goworld Co Ltd
SZSE:000823
|
CN |
|
Monte Carlo Fashions Ltd
NSE:MONTECARLO
|
IN |
Elutia Inc
Total Current Assets
Elutia Inc
Total Current Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Elutia Inc
NASDAQ:ELUT
|
Total Current Assets
$55.8m
|
CAGR 3-Years
3%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Total Current Assets
$29.1B
|
CAGR 3-Years
1%
|
CAGR 5-Years
4%
|
CAGR 10-Years
6%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Current Assets
$18.3B
|
CAGR 3-Years
8%
|
CAGR 5-Years
3%
|
CAGR 10-Years
-3%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Current Assets
$29.1B
|
CAGR 3-Years
9%
|
CAGR 5-Years
7%
|
CAGR 10-Years
-3%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Current Assets
$11.2B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
7%
|
CAGR 10-Years
23%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Current Assets
$18B
|
CAGR 3-Years
4%
|
CAGR 5-Years
13%
|
CAGR 10-Years
20%
|
|
Elutia Inc
Glance View
Aziyo Biologics, Inc. operates as a biotechnology company. The company is headquartered in Silver Spring, Maryland and currently employs 151 full-time employees. The company went IPO on 2020-10-08. The firm is a commercial-stage company that serves two markets with products based on its biomatrix platforms. The company offers a drug-eluting biologic technology: a fusion of natural biologic material and extended antibiotic release, for device implantation and soft tissue reconstruction. Its first product is CanGaroo Envelope, used for the stabilization of implantable cardiac devices, such as pacemakers and defibrillators. Its second product is SimpliDerm Acellular Dermal Matrix, used primarily in breast reconstruction following mastectomy. The company is also engaged in the development of CanGaroo RM, which adds the antibiotics rifampin and minocycline for sustained delivery directly to the surgical site. The Company’s products are used by electrophysiologists and plastic surgeons.
See Also
What is Elutia Inc's Total Current Assets?
Total Current Assets
55.8m
USD
Based on the financial report for Dec 31, 2025, Elutia Inc's Total Current Assets amounts to 55.8m USD.
What is Elutia Inc's Total Current Assets growth rate?
Total Current Assets CAGR 5Y
-1%
Over the last year, the Total Current Assets growth was 115%. The average annual Total Current Assets growth rates for Elutia Inc have been 3% over the past three years , -1% over the past five years .
